Key Points
- EVP Eric Swayze sold 23,463 Ionis shares on January 2 at an average price of $79.12 for about $1.856 million, reducing his stake by 43.52% to 30,453 shares valued around $2.41 million.
- Ionis shares were trading up (~3.8%) around $81.49 with a market cap of $13.2 billion and a 1‑year range of $23.95–$83.61; analysts have raised targets (average price target $87.05) and the consensus rating is a Moderate Buy.
- The company beat recent quarterly estimates (EPS -$0.80 vs. -$1.15 est.; revenue $156.72M, +17.2% YoY) but remains unprofitable with negative net margin and ROE, and sell‑side forecasts EPS of -3.5 for the year.
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Get Free Report) EVP Eric Swayze sold 23,463 shares of Ionis Pharmaceuticals stock in a transaction on Friday, January 2nd. The shares were sold at an average price of $79.12, for a total transaction of $1,856,392.56. Following the completion of the sale, the executive vice president owned 30,453 shares in the company, valued at approximately $2,409,441.36. This trade represents a 43.52% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.
Eric Swayze also recently made the following trade(s):
- On Thursday, October 16th, Eric Swayze sold 53 shares of Ionis Pharmaceuticals stock. The stock was sold at an average price of $73.62, for a total transaction of $3,901.86.
Ionis Pharmaceuticals Trading Up 3.8%
Shares of IONS opened at $81.49 on Wednesday. Ionis Pharmaceuticals, Inc. has a 1-year low of $23.95 and a 1-year high of $83.61. The company has a current ratio of 2.79, a quick ratio of 2.78 and a debt-to-equity ratio of 0.96. The firm's 50-day moving average price is $77.67 and its 200-day moving average price is $61.60. The firm has a market capitalization of $13.20 billion, a price-to-earnings ratio of -48.22 and a beta of 0.28.
Ionis Pharmaceuticals (NASDAQ:IONS - Get Free Report) last released its quarterly earnings results on Wednesday, October 29th. The company reported ($0.80) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.15) by $0.35. The company had revenue of $156.72 million during the quarter, compared to the consensus estimate of $131.75 million. Ionis Pharmaceuticals had a negative net margin of 26.45% and a negative return on equity of 44.26%. Ionis Pharmaceuticals's revenue was up 17.2% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.95) earnings per share. Sell-side analysts anticipate that Ionis Pharmaceuticals, Inc. will post -3.5 EPS for the current year.
Institutional Trading of Ionis Pharmaceuticals
A number of institutional investors and hedge funds have recently bought and sold shares of the company. Golden State Wealth Management LLC lifted its stake in shares of Ionis Pharmaceuticals by 198.4% in the third quarter. Golden State Wealth Management LLC now owns 376 shares of the company's stock worth $25,000 after buying an additional 250 shares in the last quarter. Steigerwald Gordon & Koch Inc. bought a new stake in shares of Ionis Pharmaceuticals during the third quarter valued at approximately $25,000. Mather Group LLC. purchased a new position in Ionis Pharmaceuticals in the 3rd quarter worth approximately $27,000. Quarry LP bought a new position in Ionis Pharmaceuticals during the 3rd quarter valued at about $38,000. Finally, Johnson Financial Group Inc. bought a new stake in Ionis Pharmaceuticals in the 3rd quarter worth approximately $44,000. 93.86% of the stock is currently owned by institutional investors.
Analyst Ratings Changes
Several equities research analysts recently weighed in on IONS shares. Leerink Partners upped their price target on Ionis Pharmaceuticals from $85.00 to $100.00 and gave the stock an "outperform" rating in a research note on Monday, December 15th. Wells Fargo & Company upped their target price on shares of Ionis Pharmaceuticals from $82.00 to $100.00 and gave the stock an "overweight" rating in a research report on Monday. Stifel Nicolaus increased their price target on shares of Ionis Pharmaceuticals from $43.00 to $67.00 and gave the stock a "hold" rating in a research note on Monday, October 6th. Barclays boosted their price objective on shares of Ionis Pharmaceuticals from $80.00 to $95.00 and gave the stock an "overweight" rating in a research note on Thursday, October 30th. Finally, JPMorgan Chase & Co. raised shares of Ionis Pharmaceuticals from a "neutral" rating to an "overweight" rating and raised their target price for the company from $49.00 to $80.00 in a research note on Wednesday, October 8th. One research analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average price target of $87.05.
Read Our Latest Stock Report on Ionis Pharmaceuticals
Ionis Pharmaceuticals Company Profile
(
Get Free Report)
Ionis Pharmaceuticals, Inc is a biotechnology company focused on the discovery and development of RNA-targeted therapies designed to modulate gene expression. The company's proprietary antisense oligonucleotide (ASO) technology enables the selective binding of short synthetic strands of nucleic acids to messenger RNA (mRNA), thereby inhibiting or altering the production of disease-causing proteins. Ionis' pipeline spans a range of therapeutic areas, including neurological disorders, cardiovascular conditions, metabolic diseases and rare genetic disorders.
Since its founding in 1989 by Dr.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
